People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kytopen Corp. | — | Biotechnology | Series B | $52.7M | $39.0M | 2024 |
Paul Wotton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Wotton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann DeWitt | 1 | 10 |
| Paxton Major | 1 | 5 |
| Edward Freedman | 1 | 3 |
| Julio Vega | 1 | 3 |
| Theresa Tribble | 1 | 3 |
| Michael Chiu | 1 | 2 |
| Paulo Garcia | 1 | 1 |
| Cullen Buie | 1 | 1 |
| Bethany Grant | 1 | 1 |
| Adam Wieschhaus | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.